Physician
Al Kassar, Ghiath
Al Kassar, Ghiath was paid $6.43M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 35% of everything it billed.
33Billing provider infoAL KASSAR, GHIATH
BOLINGBROOK, IL 60440
BOLINGBROOK, IL 60440
33aNPI1396939500assigned 08/30/2007
33bProvider typePediatrics Physician
28Total paid$6.43M
24GClaims239,135
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Illinois
Rank by total paid#5 of 1,805
Median peer was paid$55K
This provider vs. median116×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,045 | $623K | |
| 2019 | 28,511 | $686K | |
| 2020 | 33,374 | $775K | |
| 2021 | 35,037 | $840K | |
| 2022 | 45,196 | $1.19M | |
| 2023 | 41,372 | $1.14M | |
| 2024incomplete | 35,600 | $1.17M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 35% | 45,547 | 35,494 | $2.24M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 13,764 | 10,649 | $1.06M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 7.6% | 6,453 | 4,929 | $490K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 5.7% | 5,365 | 4,442 | $365K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 5.3% | 6,746 | 5,615 | $342K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.1% | 3,504 | 3,086 | $262K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.0% | 2,381 | 2,003 | $195K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.7% | 11,433 | 9,199 | $177K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.6% | 5,566 | 4,541 | $170K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 2.5% | 480 | 439 | $163K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.1% | 8,770 | 7,335 | $137K |
| 96127 | 1.3% | 5,786 | 4,916 | $83K |
79 more codes
| 99381 | 1.2% | 915 | $79K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 3,166 | $73K |
| 90670 | 1.0% | 4,048 | $65K | |
| 83655 | <1% | 4,641 | $54K | |
| 90677 | <1% | 654 | $38K | |
| 99173 | <1% | 4,795 | $36K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,360 | $33K |
| 90633 | <1% | 2,893 | $32K | |
| 90681 | <1% | 2,495 | $32K | |
| 90648 | <1% | 3,311 | $28K | |
| 90710 | <1% | 2,063 | $27K | |
| 36416 | <1% | 6,639 | $27K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 587 | $25K |
| 90697 | <1% | 1,303 | $20K | |
| 90723 | <1% | 2,062 | $18K | |
| 85018 | <1% | 7,540 | $17K | |
| 90734 | <1% | 1,098 | $17K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,115 | $13K |
| 90700 | <1% | 951 | $10K | |
| 90686 | <1% | 1,066 | $10K | |
| 90696 | <1% | 771 | $10K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,890 | $9K |
| 99406 | <1% | 1,092 | $8K | |
| 86328 | <1% | 137 | $6K | |
| 90715 | <1% | 475 | $6K | |
| 96160 | <1% | 693 | $5K | |
| 90716 | <1% | 242 | $5K | |
| 92551 | <1% | 311 | $5K | |
| 99407 | <1% | 312 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 470 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 171 | $4K |
| 90651 | <1% | 228 | $4K | |
| 90707 | <1% | 251 | $4K | |
| 90620 | <1% | 251 | $4K | |
| 99383 | <1% | 18 | $2K | |
| 95165 | Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials | <1% | 20 | $2K |
| 90647 | <1% | 121 | $1K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 14 | $1K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 24 | $847.92 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 356 | $389.00 |
| 99421 | <1% | 21 | $276.99 | |
| 81003 | <1% | 112 | $244.16 | |
| 95117 | <1% | 21 | $174.30 | |
| 90685 | <1% | 18 | $137.01 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13 | $4.03 |
| 1159F | <1% | 21,479 | $0.39 | |
| 1160F | <1% | 21,704 | $0.38 | |
| 0545F | 0% | 127 | $0.00 | |
| 4045F | 0% | 739 | $0.00 | |
| 3080F | 0% | 781 | $0.00 | |
| 4000F | 0% | 665 | $0.00 | |
| 3079F | 0% | 783 | $0.00 | |
| 3352F | 0% | 440 | $0.00 | |
| 2000F | 0% | 787 | $0.00 | |
| 1220F | 0% | 1,157 | $0.00 | |
| 3075F | 0% | 781 | $0.00 | |
| 3074F | 0% | 784 | $0.00 | |
| 3353F | 0% | 315 | $0.00 | |
| 1036F | 0% | 315 | $0.00 | |
| 3351F | 0% | 440 | $0.00 | |
| 4063F | 0% | 127 | $0.00 | |
| 4060F | 0% | 314 | $0.00 | |
| 1035F | 0% | 314 | $0.00 | |
| 3354F | 0% | 441 | $0.00 | |
| 1000F | 0% | 127 | $0.00 | |
| 2060F | 0% | 440 | $0.00 | |
| 3085F | 0% | 1,168 | $0.00 | |
| 4001F | 0% | 666 | $0.00 | |
| 3210F | 0% | 2,687 | $0.00 | |
| 1033F | 0% | 1,048 | $0.00 | |
| 3725F | 0% | 614 | $0.00 | |
| 4274F | 0% | 403 | $0.00 | |
| 99072 | 0% | 71 | $0.00 | |
| 3077F | 0% | 781 | $0.00 | |
| 3078F | 0% | 781 | $0.00 | |
| 1040F | 0% | 315 | $0.00 | |
| 4004F | 0% | 541 | $0.00 | |
| 4062F | 0% | 441 | $0.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.